The N°. 66 recommendation of AIFA (Italian Agency - Pharmaceutical Association) warns against the risk cardiac and cerebral patients may undergo when taking high dosage of NSAID. Patients affected by neuropatic pain now have a new treatment: a self injectable low dosage (25,50 75mg) of Diclofenac. The symposium, sponsored by IBSA on occasion of the 67° SIIARTI Congress, sees the participation of key experts, of different fields and formation, focusing on their experiences and future developments.
The N°. 66 recommendation of AIFA (Italian Agency - Pharmaceutical Association) warns against the risk cardiac and cerebral patients may undergo when taking high dosage of NSAID. Patients affected by neuropatic pain now have a new treatment: a self injectable low dosage (25,50 75mg) of Diclofenac. The symposium, sponsored by IBSA on occasion of the 67° SIIARTI Congress, sees the participation of key experts, of different fields and formation, focusing on their experiences and future developments.
presentations
New injectable Diclofenac formulation - 1^ part
New injectable Diclofenac formulation - 2^ part
Could NSAID be used in neuropatic pain?
NSAID and peripheral control of neuropatic pain
AIFA warning on NSAID dosage and new formulations
speakers' interviews
Low dosage injectable Diclofenac: AIFA guidelines
New Diclofenac formulation also for cardiac patients
When NSAID can be effective in nociceptive pain
